Erratum: Elevated levels of IL-18 in plasma and skeletal muscle in chronic obstructive pulmonary disease (Lung (2007) 185 (161-171) DOI 10.1007/s00408-007-9000-7);Elevated levels of IL-18 in plasma and skeletal muscle in chronic obstructive pulmonary disease

Lung

Volumn 185, Issue 3, 2007, Pages 161-171

  Petersen, A M W ^a,b   Penkowa, M ^a,c   Iversen, M ^a   Frydelund Larsen, L ^a,b   Andersen, J L ^b   Mortensen, J ^a   Lange, P ^a   Pedersen, B K ^a,b,d  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d Rigshospitalet   (Denmark)

Author keywords

COPD; Cytokines; Inflammation; Interleukin 18; Muscle

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; INTERLEUKIN 18; INTERLEUKIN 6; STEROID; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LOW DRUG DOSE; MALE; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SKELETAL MUSCLE; TISSUE LEVEL; WEIGHT REDUCTION;

EID: 34249811804     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-011-9330-3     Document Type: Erratum

References (52)

1. Betz R, Kohlhaufl M, Kassner G, et al. (2001) Increased sputum IL-8 and IL-5 in asymptomatic nonspecific airway hyperresponsiveness. Lung 179(2):119-133
2. Chung KF (2001) Cytokines in chronic obstructive pulmonary disease. Eur Respir J 18(Suppl 34):50-59
3. Decramer M, De BF, Del PA, Marinari S (2005) Systemic effects of COPD. Respir Med 99 Suppl B:S3-S10
4. Jeffery PK, Laitinen A, Venge P (2000) Biopsy markers of airway inflammation and remodelling. Respir Med 94 Suppl F:S9-S15
5. Anker SD, Coats AJ (1999) Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation. Chest 115(3):836-847
6. Schols AM, Slangen J, Volovics L, Wouters EF (1998) Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157(6 Pt 1):1791-1797
7. Lacasse Y, Wong E, Guyatt GH, et al. (1996) Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. Lancet 348:1115-1119
8. Dekhuijzen PN, van Herwaarden CL, Cox NJ, Folgering HT (1990) Exercise training during pulmonary rehabilitation in chronic obstructive pulmonary disease. Lung 168 Suppl:481-488
9. Di Francia M, Barbier D, Mege JL, Orehek J (1994) Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 150(5 Pt 1):1453-1455
10. de Godoy I, Donahoe M, Calhoun WJ, Mancino J, Rogers RM (1996) Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients. Am J Respir Crit Care Med 153(2):633-637
11. Higham MA, Pride NB, Alikhan A, Morrell NW (2000) Tumour necrosis factor-alpha gene promoter polymorphism in chronic obstructive pulmonary disease. Eur Respir J 15(2):281-284
12. Van Helvoort HA, Heijdra YF, Thijs HM, et al. (2006) Exercise-induced systemic effects in muscle-wasted patients with COPD. Med Sci Sports Exerc 38(9):1543-1552
13. Schols AM, Buurman WA, Staal van den Brekel AJ, Dentener MA, Wouters EF (1996) Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 51(8):819-824
14. Montes de OM, Torres SH, De SJ, et al. (2005) Skeletal muscle inflammation and nitric oxide in patients with COPD. Eur Respir J 26(3):390-397
15. Rabinovich RA, Figueras M, Ardite E, et al. (2003) Increased tumour necrosis factor-alpha plasma levels during moderate-intensity exercise in COPD patients. Eur Respir J 21(5):789-794
16. Kashiwamura S, Ueda H, Okamura H (2002) Roles of interleukin-18 in tissue destruction and compensatory reactions. J Immunother 25 Suppl 1:S4-S11
17. Dinarello CA, Novick D, Puren AJ, et al. (1998) Overview of interleukin-18: more than an interferon-gamma inducing factor. J Leukoc Biol 63(6):658-664
18. Ghayur T, Banerjee S, Hugunin M, et al. (1997) Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature 386(6625):619-623
19. Gu Y, Kuida K, Tsutsui H, et al. (1997) Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme. Science 275(5297):206-209
20. Bazan JF, Timans JC, Kastelein RA (1996) A newly defined interleukin-1? Nature 379(6566):591
21. Suzuki N, Suzuki S, Duncan GS, et al. (2002) Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature 416(6882):750-756
22. Plomgaard P, Penkowa M, Pedersen BK (2005) Fiber type specific expression of TNF-alpha, IL-6 and IL-18 in human skeletal muscles. Exerc Immunol Rev 11:53-63
23. Hiscock N, Chan MH, Bisucci T, Darby IA, Febbraio MA (2004) Skeletal myocytes are a source of interleukin-6 mRNA expression and protein release during contraction: evidence of fiber type specificity. FASEB J 18(9):992-994
24. Krogh-Madsen R, Plomgaard P, Moller K, Mittendorfer B, Pedersen BK (2006) Influence of TNF-alpha and IL-6 infusions on insulin sensitivity and expression of IL-18 in humans. Am J Physiol Endocrinol Metab 291(1):E108-E114
25. Pauwels RA, Buist AS, Ma P, Jenkins CR, Hurd SS (2001) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care 46(8):798-825
26. Klausen K, Andersen LB, Pelle I (1981) Adaptive changes in work capacity, skeletal muscle capillarization and enzyme levels during training and detraining. Acta Physiol Scand 113(1):9-16
27. Carr A, Emery S, Law M, et al. (2003) An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 361(9359):726-735
28. Steensberg A, Febbraio MA, Osada T, et al. (2001) Interleukin-6 production in contracting human skeletal muscle is influenced by pre-exercise muscle glycogen content. J Physiol (Lond) 537(Pt 2):633-639
29. Brooke MH, Kaiser KK (1970) Muscle fiber types: how many and what kind? Arch Neurol 23(4):369-379
30. Brooke MH, Kaiser KK (1970) Three "myosin adenosine triphosphatase" systems: the nature of their pH lability and sulfhydryl dependence. J Histochem Cytochem 18(9):670-672
31. Andersen JL, Aagaard P (2000) Myosin heavy chain IIX overshoot in human skeletal muscle. Muscle Nerve 23(7):1095-1104
32. Qu Z, Andersen JL, Zhou S (1997) Visualisation of capillaries in human skeletal muscle. Histochem Cell Biol 107(2):169-174
33. Puren AJ, Razeghi P, Fantuzzi G, Dinarello CA (1998) Interleukin-18 enhances lipopolysaccharide-induced interferon-gamma production in human whole blood cultures. J Infect Dis 178(6):1830-1834
34. Keller C, Steensberg A, Pilegaard H, et al. (2001) Transcriptional activation of the IL-6 gene in human contracting skeletal muscle: influence of muscle glycogen content. FASEB J 15(14):2748-2750
35. Penkowa M, Keller C, Keller P, Jauffred S, Pedersen BK (2003) Immunohistochemical detection of interleukin-6 in human skeletal muscle fibers following exercise. FASEB J 17(14):2166-2168
36. Akerstrom TC, Steensberg A, Keller P, et al. (2005) Exercise induces interleukin-8 expression in human skeletal muscle. J Physiol 563:507-516
37. Majori M, Corradi M, Caminati A, et al. (1999) Predominant TH1 cytokine pattern in peripheral blood from subjects with chronic obstructive pulmonary disease. J Allergy Clin Immunol 103(3 Pt 1):458-462
38. Esposito K, Marfella R, Giugliano D (2004) Plasma interleukin-18 concentrations are elevated in type 2 diabetes. Diabetes Care 27(1):272
39. Sauerwein HP, Schols AM (2002) Glucose metabolism in chronic lung disease. Clin Nutr 21(5):367-371
40. Hotamisligil GS, Peraldi P, Budavari A, et al. (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271(5249):665-668
41. Gosker HR, van Mameren H, van Dijk PJ, et al. (2002) Skeletal muscle fibre-type shifting and metabolic profile in patients with chronic obstructive pulmonary disease. Eur Respir J 19(4):617-625
42. Burnham R, Martin T, Stein R, et al. (1997) Skeletal muscle fibre type transformation following spinal cord injury. Spinal Cord 35(2):86-91
43. Hoppeler H, Vogt M, Weibel ER, Fluck M (2003) Response of skeletal muscle mitochondria to hypoxia. Exp Physiol 88(1):109-119
44. Hoppeler H (1999) Vascular growth in hypoxic skeletal muscle. Adv Exp Med Biol 474:277-286
45. Gosker HR, Wouters EF, van der Vusse GJ, Schols AM (2000) Skeletal muscle dysfunction in chronic obstructive pulmonary disease and chronic heart failure: underlying mechanisms and therapy perspectives. Am J Clin Nutr 71(5):1033-1047
46. Nakamura S, Otani T, Ijiri Y, et al. (2000) IFN-gamma-dependent and -independent mechanisms in adverse effects caused by concomitant administration of IL-18 and IL-12. J Immunol 164(6):3330-3336
47. Chikano S, Sawada K, Shimoyama T, et al. (2000) IL-18 and IL-12 induce intestinal inflammation and fatty liver in mice in an IFN-gamma dependent manner. Gut 47(6):779-786
48. Novota P, Kolostova K, Pinterova D, et al. (2005) Interleukin IL-18 gene promoter polymorphisms in adult patients with type 1 diabetes mellitus and latent autoimmune diabetes in adults. Immunol Lett 96(2):247-251
49. Esposito K, Pontillo A, Ciotola M, et al. (2002) Weight loss reduces interleukin-18 levels in obese women. J Clin Endocrinol Metab 87(8):3864-3866
50. Lindegaard B, Hansen AE, Gerstoft J, Pedersen BK (2004) High plasma level of IL-18 in HIV-infected patients with lipodystrophy. J Acquir Immune Defic Syndr 36(1):588-593
51. Agusti AG, Sauleda J, Miralles C, et al. (2002) Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 166(4):485-489
52. Hashimoto W, Osaki T, Okamura H, et al. (1999) Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively. J Immunol 163(2):583-589